Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Amgen Ventures
Deal Size : $46.0 million
Deal Type : Series C Financing
Casma Therapeutics Raises $46.0 M in Series C Funding
Details : Casma will use proceeds to advance its lead program for MYD88 mutant lymphoma through preclinical and into IND enabling studies.The closing of this financing has strengthened our resources to continue advancing our drug pipeline focused on autophagy-base...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 15, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Amgen Ventures
Deal Size : $46.0 million
Deal Type : Series C Financing